financetom
Business
financetom
/
Business
/
MicroStrategy Shares Are Falling Today: What's Going On?
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
MicroStrategy Shares Are Falling Today: What's Going On?
Dec 26, 2024 11:51 AM

MicroStrategy Inc. ( MSTR ) shares are trading lower Thursday driven by a Bitcoin pullback and investor reaction to the company's plans to issue additional shares to fund further Bitcoin purchases.

What To Know: In a filing with the SEC, the company proposed increasing its authorized Class A common stock from 330 million to 10.33 billion units and preferred stock from 5 million to over 1 billion units. This move is intended to support the company's strategy of accumulating Bitcoin, a cornerstone of its transition from software to cryptocurrency investment.

Bitcoin's recent volatility, with a peak near $100,000 and subsequent fluctuations, has added pressure on MicroStrategy's ( MSTR ) stock. The company recently acquired $561 million worth of Bitcoin, bringing its total holdings to approximately $40 billion. However, its aggressive Bitcoin purchases and reliance on stock issuance to fund acquisitions have drawn investor scrutiny.

MicroStrategy ( MSTR ) shares have faced significant challenges, including a more than 37% decline from their all-time high and an 8.5% drop following their inclusion in the Nasdaq 100. The ongoing stock issuance and Bitcoin market volatility continue to weigh on investor sentiment.

MSTR Price Action: MicroStrategy ( MSTR ) shares were down 4.16% at $343.06 at the time of writing, according to Benzinga Pro.

Read Next:

A Billionaire Set Us Up Perfectly for This Options Trade

Image Via Shutterstock.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
South Korea wants workers detained in immigration raid to be able to re-enter US
South Korea wants workers detained in immigration raid to be able to re-enter US
Sep 8, 2025
* Hyundai, LG Energy's $4.3 billion project site in Georgia raided * South Korea plans chartered flight for detained workers' return * Seoul also seeking to have US visa system for Koreans streamlined (Recasts and writes through with foreign and finance ministers' comments) By Joyce Lee and Hyunjoo Jin SEOUL, Sept 8 (Reuters) - South Korea said on Monday that...
Stellantis to scrap target of 100% EVs by 2030, says Europe chief
Stellantis to scrap target of 100% EVs by 2030, says Europe chief
Sep 8, 2025
MUNICH (Reuters) -Franco-Italian carmaker Stellantis will no longer pursue a target of producing only electric vehicles by 2030, said Jean-Philippe Imparato, head of enlarged Europe, on Monday, adding that other goals in its upcoming strategic plan known as 'Dare Forward may remain. Speaking during a roundtable at the Munich car show, Imparato also said that the European Union's carbon emissions...
Update: Ideaya, Partner Say Small Cell Lung Cancer Phase 1 Trial Shows Strong Response Rate
Update: Ideaya, Partner Say Small Cell Lung Cancer Phase 1 Trial Shows Strong Response Rate
Sep 8, 2025
05:16 AM EDT, 09/08/2025 (MT Newswires) -- (Updates with the stock price movement in the last paragraph.) Ideaya Biosciences ( IDYA ) and Hengrui Pharma said Sunday that initial data from a phase 1 trial of the experimental IDE849 small cell lung cancer treatment showed strong overall response and disease control rates across all tested doses and stages of treatment,...
Merck Says Phase 2 Study of Potential Lung Cancer Drug Showed 'Clinically Meaningful' Response Rates
Merck Says Phase 2 Study of Potential Lung Cancer Drug Showed 'Clinically Meaningful' Response Rates
Sep 8, 2025
05:35 AM EDT, 09/08/2025 (MT Newswires) -- Merck ( MRK ) said Sunday that results from its IDeate-Lung01 phase 2 trial evaluating ifinatamab deruxtecan in patients with previously treated extensive-stage small cell lung cancer showed clinically meaningful response rates. The company said patients who received ifinatamab deruxtecan in both parts of its trial, dose optimization and single-arm expansion, displayed an...
Copyright 2023-2026 - www.financetom.com All Rights Reserved